Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Elevation’s anti-Claudin18.2 antibody-drug conjugate generates some justified optimism, but Zai Lab’s zolbetuximab challenger is out of luck.
The limited activity of Reblozyl in myelodysplastic syndromes patients without ringed sideroblasts could help Geron.
Regeneron’s fianlimab could be biopharma’s most potent Lag3 project, and has shown activity in a new melanoma setting